[HTML][HTML] Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer that progressed …
J Baselga, KA Gelmon, S Verma… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
J Baselga, KA Gelmon, S Verma, A Wardley, PF Conte, D Miles, G Bianchi, J Cortes…
Journal of clinical oncology, 2010•ncbi.nlm.nih.govPurpose Pertuzumab, a human epidermal growth factor receptor 2 (HER2)–targeted
monoclonal antibody, potently inhibits HER2 dimerization and HER-mediated signaling
pathways. Pertuzumab and the approved HER2-targeted monoclonal antibody trastuzumab
have complementary mechanisms of action and result in enhanced antitumor activity when
combined. This phase II trial assessed the efficacy and safety profile of the combination in
patients with HER2-positive breast cancer whose disease had progressed during prior …
monoclonal antibody, potently inhibits HER2 dimerization and HER-mediated signaling
pathways. Pertuzumab and the approved HER2-targeted monoclonal antibody trastuzumab
have complementary mechanisms of action and result in enhanced antitumor activity when
combined. This phase II trial assessed the efficacy and safety profile of the combination in
patients with HER2-positive breast cancer whose disease had progressed during prior …
Abstract
Purpose
Pertuzumab, a human epidermal growth factor receptor 2 (HER2)–targeted monoclonal antibody, potently inhibits HER2 dimerization and HER-mediated signaling pathways. Pertuzumab and the approved HER2-targeted monoclonal antibody trastuzumab have complementary mechanisms of action and result in enhanced antitumor activity when combined. This phase II trial assessed the efficacy and safety profile of the combination in patients with HER2-positive breast cancer whose disease had progressed during prior trastuzumab-based therapy.
ncbi.nlm.nih.gov